What Researchers Did
This review article discussed current and emerging treatment options for refractory inflammatory bowel disease (IBD) and provided updates on managing acute severe ulcerative colitis (ASUC).
What They Found
Researchers noted that nearly one-third of IBD patients do not achieve remission with standard therapies. They found increasing interest in combination biologics and early promise for hyperbaric oxygen, mesenchymal stem cell therapy, and dietary interventions, while infliximab, cyclosporine, and tofacitinib show promise for acute severe ulcerative colitis.
What This Means for Canadian Patients
Canadian patients with refractory IBD may benefit from referral to an IBD centre for multidisciplinary care to explore advanced treatment options. These options could include escalation of biologics, combination therapies, or surgical interventions, offering hope for those who have not responded to initial treatments.
Canadian Relevance
This study does not have a direct Canadian connection as it was not conducted in Canada or by Canadian researchers.
Study Limitations
The review highlights that significant knowledge gaps remain in managing refractory IBD, with limited data supporting the safety and effectiveness of some emerging therapies, necessitating larger prospective studies.